

## Dear Author

Here are the proofs of your article.

- This article has a short turn-around time. We need to receive your corrections **within 48 hours**. If we do not receive your corrections within 48 hours, we will send you a reminder. Succeeding reminders will be sent every 24 hours until we receive your corrections.
- You can submit your corrections **online**, via **e-mail** or by **fax**.
- For **online** submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.
- You can also insert your corrections in the proof PDF and **email** the annotated PDF.
- For **fax** submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.
- Remember to note the **journal title**, **article number**, and **your name** when sending your response via e-mail or fax.
- **Check** the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.
- **Check** the questions that may have arisen during copy editing and insert your answers/corrections.
- **Check** that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the *Edited manuscript*.
- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.
- Please **do not** make changes that involve only matters of style. We have generally introduced forms that follow the journal's style. Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.
- Your article will be published **Online First** approximately three working days after receipt of your corrected proofs. This is the **official first publication** citable with the DOI. **Further changes are, therefore, not possible.**
- The **printed version** will follow in a forthcoming issue.

### Please note

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL:

<http://dx.doi.org/10.1208/s12249-014-0115-x>

If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information, go to: <http://www.springerlink.com>.

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us, if you would like to have these documents returned.

## Metadata of the article that will be visualized in OnlineFirst

|    |                          |  |  |
|----|--------------------------|--|--|
| 1  | Article Title            | <b>Investigation of the Cytotoxic Effects of Titanate Nanotubes on Caco-2 Cells</b>                                  |  |
| 2  | Article Sub- Title       |  |  |
| 3  | Article Copyright - Year | <b>American Association of Pharmaceutical Scientists 2014<br/>(This will be the copyright line in the final PDF)</b> |  |
| 4  | Journal Name             | AAPS PharmSciTech  |  |
| 5  |                          | Family Name  | <b>Bácskay</b>   |
| 6  |                          | Particle   |  |
| 7  |                          | Given Name   | <b>Ildikó</b>  |
| 8  | Corresponding            | Suffix   |  |
| 9  | Author                   | Organization   | University of Debrecen   |
| 10 |                          | Division   | Department of Pharmaceutical Technology  |
| 11 |                          | Address  | Nagyerdei krt. 98, Debrecen 4010, Hungary  |
| 12 |                          | e-mail   | bacskay.ildiko@pharm.unideb.hu   |
| 13 |                          | Family Name  | <b>Fenyvesi</b>  |
| 14 |                          | Particle   |  |
| 15 |                          | Given Name   | <b>Ferenc</b>  |
| 16 |                          | Suffix   |  |
| 17 | Author                   | Organization   | University of Debrecen   |
| 18 |                          | Division   | Department of Pharmaceutical Technology  |
| 19 |                          | Address  | Nagyerdei krt. 98, Debrecen 4010, Hungary  |
| 20 |                          | e-mail   |  |
| 21 |                          | Family Name  | <b>Kónya</b>   |
| 22 |                          | Particle   |  |
| 23 |                          | Given Name   | <b>Zoltán</b>  |
| 24 |                          | Suffix   |  |
| 25 | Author                   | Organization   | University of Szeged and MTA-SZTE Reaction Kinetics and Surface Chemistry Research Group |
| 26 |                          | Division   | Department of Applied and Environmental Chemistry  |
| 27 |                          | Address  | Rerrich ter 1, Szeged 6720, Hungary  |
| 28 |                          | e-mail   |  |
| 29 | Author                   | Family Name  | <b>Rázga</b>   |

|       |          |  |   |
|-------|----------|--|---|
| 30    |          | Particle   |   |
| 31    |          | Given Name   | <b>Zsolt</b>                              |
| 32    |          | Suffix   |   |
| 33    |          | Organization   | University of Szeged                      |
| 34    |          | Division   | Department of Pathology                   |
| 35    |          | Address  | Állomás utca 2, Szeged 6725, Hungary      |
| 36    |          | e-mail   |   |
| <hr/> |          |  |   |
| 37    |          | Family Name  | <b>Vecsernyés</b>                         |
| 38    |          | Particle   |   |
| 39    |          | Given Name   | <b>Miklós</b>                             |
| 40    |          | Suffix   |   |
| 41    | Author   | Organization   | University of Debrecen                    |
| 42    |          | Division   | Department of Pharmaceutical Technology   |
| 43    |          | Address  | Nagyerdei krt. 98, Debrecen 4010, Hungary |
| 44    |          | e-mail   |   |
| <hr/> |          |  |   |
| 45    |          | Family Name  | <b>Kása</b>                               |
| 46    |          | Particle   |   |
| 47    |          | Given Name   | <b>Péter</b>                              |
| 48    |          | Suffix   | <b>Jr.</b>                                |
| 49    | Author   | Organization   | University of Szeged                      |
| 50    |          | Division   | Department of Pharmaceutical Technology   |
| 51    |          | Address  | Eötvös utca 6, Szeged 6720, Hungary       |
| 52    |          | e-mail   |   |
| <hr/> |          |  |   |
| 53    |          | Family Name  | <b>Pintye-Hódi</b>                        |
| 54    |          | Particle   |   |
| 55    |          | Given Name   | <b>Klára</b>                              |
| 56    |          | Suffix   |   |
| 57    | Author   | Organization   | University of Szeged                      |
| 58    |          | Division   | Department of Pharmaceutical Technology   |
| 59    |          | Address  | Eötvös utca 6, Szeged 6720, Hungary       |
| 60    |          | e-mail   |   |
| <hr/> |          |  |   |
| 61    |          | Received   | 7 November 2013                           |
| 62    | Schedule | Revised  |   |
| 63    |          | Accepted   | 13 March 2014                             |
| <hr/> |          |  |   |
| 64    | Abstract | Titanate nanotubes can be used as drug delivery systems, but limited information is available on their interactions with intestinal cells. In this study, we investigated the cytotoxicity and cellular uptake of titanate nanotubes on Caco-2 monolayers and found that |   |

up to 5 mg/ml concentration, these nanotubes are not cytotoxic and not able to permeate through the intestinal cell layer. Transmission electron microscopic experiments showed that titanate nanotubes are not taken up by cells, only caused a high-density granulation on the surface of the endoplasmic reticulum. According to these results, titanate nanotubes are suitable systems for intestinal drug delivery.

- 
- 65 Keywords Caco-2 cells - cytotoxicity - titanate nanotubes  
separated by ' - '
- 
- 66 Foot note  
information

## Rapid Communication

## Investigation of the Cytotoxic Effects of Titanate Nanotubes on Caco-2 Cells

Ferenc Fenyvesi,<sup>1</sup> Zoltán Kónya,<sup>2</sup> Zsolt Rázga,<sup>3</sup> Miklós Vecsernyés,<sup>1</sup> Péter Kása Jr.,<sup>4</sup>  
Klára Pintye-Hódi,<sup>4</sup> and Ildikó Bácskay<sup>1,5</sup>

Received 7 November 2013; accepted 13 March 2014

**Abstract.** Titanate nanotubes can be used as drug delivery systems, but limited information is available on their interactions with intestinal cells. In this study, we investigated the cytotoxicity and cellular uptake of titanate nanotubes on Caco-2 monolayers and found that up to 5 mg/ml concentration, these nanotubes are not cytotoxic and not able to permeate through the intestinal cell layer. Transmission electron microscopic experiments showed that titanate nanotubes are not taken up by cells, only caused a high-density granulation on the surface of the endoplasmic reticulum. According to these results, titanate nanotubes are suitable systems for intestinal drug delivery.

**KEY WORDS:** Caco-2 cells; cytotoxicity; titanate nanotubes.

## INTRODUCTION

Carbon and titanate nanotubes (TiNT) are specific types of nanoparticles (1,2) with the advantage that small particles of active pharmaceutical ingredients (APIs) can be incorporated into the nanotube cavity (3). With nanotube technology, it is possible to prepare stable drug delivery systems, but their safety is a key issue that remains to be resolved. Several publications have reported on the application of carbon nanotubes (4,5), but toxicity studies have not been conclusive (6). Accordingly, the absorption, toxicity and cellular effects of nanotubes should be investigated for a full characterization of their effects. Only limited information is available concerning the cellular effects of TiNT in the gastrointestinal tract, and we have therefore studied their toxicity and absorption through the use of the Caco-2-cell line.

## MATERIALS AND METHODS

## Preparation of Titanate Nanotubes

TiNTs were synthesized by a simple alkali hydrothermal method involving the alkaline recrystallization of anatase TiO<sub>2</sub>, as described previously (7,8). The material obtained was

characterized by transmission electron microscopy (TEM; Philips CM10, 100 kV), scanning electron microscopy (SEM; Hitachi S4700; Hitachi Scientific Instruments Ltd., Japan) and X-ray diffractometry (XRD; Rigaku miniflex 2000, CuK<sub>α</sub>). Its specific surface area was determined from nitrogen adsorption measurements performed at 77 K in a Quantachrome Nova 3000e instrument and analysed by the BET method.

## Cell Culture and MTT Cell Viability Test

Caco-2 cells were used for permeability and cytotoxicity experiments. Cells were seeded on Transwell® (Corning Costar, USA) filters as reported previously (9). The cellular uptake of TiNT was examined by TEM as described in Fig. 3. To test TiNT cytotoxicity by the MTT method (10), Caco-2 cells were seeded in 96-well plates, and cells were exposed to increasing TiNT concentrations in Hank's balanced salt solution (HBSS) at 37°C for 120 min. Dye absorbance was measured at 570 nm with a FLUOstar OPTIMA microplate reader (BMG LABTECH, Offenburg, Germany), and the values were corrected for the background absorbance, measured at 690 nm. Cell viability was expressed as a percentage of the untreated control. All reagents were purchased from Sigma-Aldrich (Budapest, Hungary).

## Caco-2 Permeability Experiments

In permeability experiments, Caco-2 monolayers were incubated apically with TiNT at 2 mg/ml for 120 min. Then, the permeated amount of Ti was measured with an energy dispersive X-ray fluorescence analyser (Philips MiniPal PW 4025, Philips Analytical, the Netherlands).

## Morphology Studies

*TEM.* The morphology of the synthesized titanate nanotubes was characterized with the aid of a TECNAI G<sup>2</sup> 20 X-


<sup>1</sup> Department of Pharmaceutical Technology, University of Debrecen, 4010, Debrecen, Nagyerdei krt. 98, Hungary.

<sup>2</sup> Department of Applied and Environmental Chemistry, University of Szeged and MTA-SZTE Reaction Kinetics and Surface Chemistry Research Group, 6720, Szeged, Rerrich ter 1, Hungary.

<sup>3</sup> Department of Pathology, University of Szeged, 6725, Szeged, Állomás utca 2, Hungary.

<sup>4</sup> Department of Pharmaceutical Technology, University of Szeged, 6720, Szeged, Eötvös utca 6, Hungary.

<sup>5</sup> To whom correspondence should be addressed. (e-mail: bacskay.ildiko@pharm.unideb.hu)



**Fig. 1.** TEM (a) and SEM (b) images of TiNT

69 Twin high-resolution transmission electron microscope  
 70 operating at an accelerating voltage of 200 kV. Samples for  
 71 TEM measurements were drop casted onto carbon-coated  
 72 copper grids from an acetone suspension.

73  
 74 *SEM.* The surface of the nanotubes was tested with a  
 75 scanning electron microscope (Hitachi S4700; Hitachi Scientific  
 76 Instruments Ltd., Japan). A SEM sputter coating unit  
 77 (Polaron E5100; VG Microtech, UK) was used to charge the  
 78 surfaces for the SEM measurements.  
 79  
 80


81 **RESULTS**

82 The formation of the TiNT was examined by TEM and  
 83 SEM. Figure 1 shows that the length of the nanotubes was 50–  
 84 150 nm and their diameter was 6–10 nm. The tubular structure  
 85 can also be identified. A typical TiNT has four walls and an  
 86 interlayer of spacing approximately 0.7 nm. The specific surface  
 87 area of the TiNT is  $\sim 185 \text{ m}^2\text{g}^{-1}$  due to the specific morphology.  
 88 The as-synthesized sample (Na-form) exhibited broad peaks of  
 89 low intensity, which are quite difficult to index, but the profile


could be referred to as reflections (around  $10^\circ$ ,  $25^\circ$ ,  $28^\circ$  and  $49^\circ$ )  
 of sodium trititanate,  $\text{Na}_2\text{Ti}_3\text{O}_7$  (JCPDS no. 31-1329).

Cytotoxic effects could not be detected with the MTT  
 method up to a nanotube concentration of 5 mg/ml (Fig. 2).  
 This is in accordance with the findings that titanium dioxide  
 ( $\text{TiO}_2$ ) nanoparticles at 1 mg/ml did not cause the death of  
 Caco-2 cells (11) and that titania nanotubes up to 1.1 mg/ml  
 are non-cytotoxic on A549 lung epithelial cells (12).

In permeability experiments, no detectable amount of Ti  
 was found in the basolateral side of the monolayers, indicating  
 that intestinal cells are impermeable for TiNT. Monolayers  
 were also treated with 0.5 mg/ml TiNT, fixed with 4% glutar-  
 aldehyde and processed for TEM investigations. Nanotubes  
 could not be identified in the Caco-2 cells demonstrating  
 (Fig. 3) that these nanotubes were not taken up by the cells.  
 Nevertheless, high-density granules which had no nanotubular  
 morphology (Fig. 3c, arrows) could be observed on the surface  
 of the endoplasmic reticulum in the treated cells. These granules  
 may be titanium dioxide particles formed from the nano-  
 tubes during the incubation or  $\text{TiO}_2$  impurities. This is in  
 accordance with a previous report that at  $\geq 10 \mu\text{g/ml}$ ,  $\text{TiO}_2$   
 nanoparticles are able to enter Caco-2 cells and cross a Caco-2  
 monolayer by transcytosis (11).



**Fig. 2.** Cytotoxicity of TiNT and  $\text{TiO}_2$ . Caco-2 cells were treated with nanotubes and titanium dioxide in different concentrations for 120 min, and their viability was determined by MTT tests. Untreated control was considered as 100%, and data are expressed as the percentage of untreated control. Positive control, 2% Triton X-100 solution. There were no significant differences among TiNT- and  $\text{TiO}_2$ -treated samples ( $p > 0.05$ ), while Triton X-100 exerted complete cell death ( $p < 0.05$ ). Data are means of three independent experiments  $\pm$  SD



**Fig. 3.** TEM images of Caco-2 cells. Untreated (a and b) or titanate nanotube-treated (c) Caco-2 monolayers were fixed with 4% glutaraldehyde and examined by TEM. a A 45° cross section of an untreated Caco-2 monolayer. High-density granules (arrows) can be observed on the surface of the endoplasmic reticulum in titanate nanotube-treated cells (c) after the 30-min treatment. TEM: For the detection of cellular titanate nanotubes uptake, confluent monolayers were treated with 0.5 mg/ml titanate nanotubes for 30–120 min, washed three times with HBSS and fixed with 4% glutaraldehyde. For TEM, the samples were embedded in Embed812 (EMS, USA), and 70-nm thin sections were cut with an Ultracut S ultra-microtome (Leica, Austria). After staining with uranyl acetate and lead citrate, the sections were observed with a Phillips CM10 electron microscope (Eindhoven, the Netherlands) equipped with a Mega-view G2 digital camera and iTEM imaging analysis software (Olympus, Münster, Germany)

**DISCUSSION** 113

TiO<sub>2</sub> is a safe, widely used excipient in pharmaceutical technology, whereas TiNT is not yet applied. Our study has furnished evidence that TiNT does not cause cellular toxicity in short-term treatment and does not penetrate Caco-2 cells, but does lead to a high-density granulation on the surface of the endoplasmic reticulum. *In vitro* cytotoxicity assays (*i.e.* MTT, LDH) can predict irritancy and delayed toxicity of harmful agents (13). Nevertheless, cytotoxicity data alone are not necessarily predictive of *in vivo* issues (14), but complemented with results of morphology studies, the *in vivo* toxicity data may be estimated (15). Even if titanate nanotubes are unpermeable on intestinal cell layer, they deliver drug particles to intestinal cell surface and can also increase the solubility of active substances. The aqueous solutions are stable for months. That may be the reason that TiNTs provide new possibilities for the formulation of oral drug delivery systems (16).

**CONCLUSION** 131

It may be concluded that TiNT is a safe system for intestinal formulations, as they are practically not absorbed from the intestine.

**ACKNOWLEDGMENTS** 135

This research was supported by the European Union and the State of Hungary, co-financed by the European Social Fund in the framework of TÁMOP-4.2.2.A-11/1/KONV-2012-0047 and TÁMOP 4.2.4. A/2-11-1-2012-0001 “National Excellence Program—Elaborating and operating an inland student and researcher personal support system”.

**REFERENCES** 143

1. Chen P, Lin J, Tan KL. Carbon nanotubes: a future material of life. *IUBMB Life*. 2000;49(2):105–8. 144
2. Kasuga T, Hiramatsu M, Hoson A, Sekino T, Niihara K. Formation of titanium oxide nanotube. *Langmuir*. 1998;14:3160–3. 146
3. Li Y, Wang T, Wang J, Jiang T, Cheng G, Wang S. Functional and unmodified MWNTs for delivery of the water-insoluble drug carvedilol—a drug-loading mechanism. *Appl Surf Sci*. 2011;257(13):5663–70. 148
4. Im JS, Bai BC, Lee YS. The effect of carbon nanotubes on drug delivery in an electrosensitive transdermal drug delivery system. *Biomater*. 2010;31(6):1414–9. 149
5. Naficy S, Razal JM, Spinks GM, Wallace GG. Modulated release of dexamethasone from chitosan-carbon nanotube films. *Sens Actuators A*. 2009;155(1):120–4. 150
6. Sayes CM, Liang F, Hudson JL, Mendez J, Guo W, Beach JM, *et al.* Functionalization density dependence of single walled carbon nanotubes cytotoxicity *in vitro*. *Toxicol Lett*. 2006;161(2):135–42. 151
7. Horváth E, Kukovecz Á, Kónya Z, Kiricsi I. Hydrothermal conversion of self-assembled TiNT into nanowires in a revolving autoclave. *Chem Mater*. 2007;19:927–31. 152
8. Kukovecz Á, Hodos M, Horváth E, Radnóczy G, Kónya Z, Kiricsi I. Oriented crystal growth model explains the formation of titania nanotubes. *J Phys Chem B*. 2005;109:17781–3. 153
9. Fenyvesi F, Kiss T, Fenyvesi É, Szente L, Veszélka S, Deli MA, *et al.* Randomly methylated β-cyclodextrin derivatives enhance 154

- 170 taxol permeability through human intestinal epithelial Caco-2 cell  
171 monolayer. *J Pharm Sci.* 2011;100(11):4734–44.
- Q4 172 10. Mosmann T. Rapid colorimetric assay for cellular growth and  
173 survival: application to proliferation and cytotoxicity assays. *J*  
174 *Immunol Methods.* 1983;65:55–63.
- 175 11. Koeneman BA, Zhang Y, Westerhoff P, Chen Y, Crittenden  
176 JC, David G, *et al.* Toxicity and cellular responses of intestinal  
177 cells exposed to titanium dioxide. *Cell Biol Toxicol.*  
178 2010;26:225–38.
- 179 12. Wadhawa S, Rea C, O'Hare P, Mathur A, Roy SS, Dunlop PSM,  
180 *et al.* Comparative in vitro cytotoxicity study of carbon nanotubes  
181 and titania nanostructures on human lung epithelial cells. *J Hazard*  
182 *Mater.* 2011;191:56–61.
- 183 13. Fotakis G, Timbrell JA. In vitro cytotoxicity assays. Comparison of  
184 LDH, neutral red, MTT and protein assay in hepatoma cell lines  
185 following exposure to cadmium chloride. *Tox Lett.* 2006;160:171–7.
- 186 14. Konsoula R, Barile FA. Correlation of in vitro cytotoxicity with  
187 paracellular permeability in Caco-2 cells. *Toxicol in Vitro.*  
188 2005;19:675–84.
- 189 15. Wang Z, Sun Y, Wang D, Liu H, Boughton IR. In situ fabrication  
190 of silver nanoparticle-filled hydrogen titanate nanotube layer on  
191 metallic titanium surface for bacteriostatic and biocompatible  
192 implantation. *Int J Nanomed.* 2013;8:2903–16.
- 193 16. Zennaro L, Magro M, Vianello F, Rigo A, Mariotto G, Giarola  
194 M, *et al.* Stable aqueous solutions of naked nanotubes.  
195 *ChemPhysChem.* 2013;14:2786–92.

UNCORRECTED PROOF

## AUTHOR QUERIES

### **AUTHOR PLEASE ANSWER ALL QUERIES.**

- Q1. Please check the suggested running page title if appropriate. Otherwise, please provide short running title with maximum of 65 characters including spaces.
- Q2. Please check affiliations if captured correctly.
- Q3. "TiO<sub>2</sub> impurities" has been changed to "TiO<sub>2</sub> impurities". Please check if appropriate.
- Q4. Please check if Ref. 10 was captured correctly.

UNCORRECTED PROOF